北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品苏合香丸获得加拿大产品注册。公司现将有 关情况公告如下： 证券代码：600085 证券简称：同仁堂 公告编号：2025-011 | 产品 | 品种批准文 | 剂型 | 适应症 | 持证商 | 持证商地址 | | --- | --- | --- | --- | --- | --- | | 名称 | 号（NPN） | | | 名称 | | | | | | 1.本品为传统中药成 | 北京同 | 北京市大兴区 中关村科技园 | | | | | 分的组合。 | 仁堂股 | | | 苏合 | | | 2.传统中药用于芳香 | 份有限 | | | | 80138750 | 丸剂 | | | 区大兴生物医 | | 香丸 | | | 开窍，行气止痛。 | 公司同 | | | | | | | | 药产业基地天 | | | | | 3.传统中药用于中暑、 | 仁堂制 | 贵大街 33 号 | | | | | 心胃气痛。 | 药厂 | | 北京同仁堂股份有限公司 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-012 北京同仁堂股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次：2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 16 日 9 点 30 分 召开地点：北京市大兴区中关村科技园区大兴生物医药产业基地天贵大街 33 号北京同仁堂股份有限公司会议室 (五) 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 16 日 至2025 年 6 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:0 ...

Core Viewpoint - Tong Ren Tang's product Su He Xiang Wan has received a product license from Health Canada, marking a significant step towards potential sales in Canada, although further administrative approvals are required [1] Group 1 - The company announced that its subsidiary, Tong Ren Tang Pharmaceutical Factory, has been granted a Class III product license for Su He Xiang Wan by Health Canada [1] - The product must still undergo additional administrative approvals, including Canadian production quality system certification, before it can be sold in Canada [1] - The recent approval is not expected to have a significant impact on the company's short-term operating performance [1]

Core Insights - The health nutrition industry is undergoing structural transformation due to heightened health awareness, stricter regulations, and a return to rational consumption, leading brands to adjust pricing, optimize inventory, and focus on channel and profit model reconstruction [1][2]. Industry Overview - The health nutrition industry is entering a high-quality development phase in 2024, driven by policy, economic, capital, and technological synergies [10]. - Regulatory bodies are enhancing the registration and filing standards for health nutrition products, increasing oversight across production and sales [11]. Product Category Situation - The industry is focusing on four core consumer groups: middle-aged working individuals, high-net-worth individuals, rehabilitation needs, and the elderly [52]. - Key product categories gaining attention include immune enhancement, joint and bone care, and probiotics, while categories like anti-aging are experiencing a decline [54][56]. Financing Trends - In 2024, the number of financing events in the health nutrition industry decreased, but the total financing amount increased, with upstream companies, particularly probiotic suppliers, being favored by investors [16][17]. - The financing amount rose by 3.21 billion yuan despite a reduction in the number of financing events [18]. Sales Channel Dynamics - Private domain e-commerce has surpassed traditional pharmaceutical chains for the first time, with platforms like Douyin Global Purchase emerging as significant players in the cross-border B2C market [2][30]. - Retailers are increasingly adopting a "direct procurement" model, with over 25% of retailers sourcing products directly from manufacturers [31]. Strategic Adjustments - In response to market pressures, 60% of small and medium-sized enterprises are reducing R&D investments and shifting towards OEM models to maintain cash flow [27]. - Major brands are enhancing their channel, product, and marketing strategies, focusing on dual strategies of high-end and affordable products [26]. Consumer Preferences - The average transaction price for core products in the health nutrition sector has significantly decreased, with 31% of companies reporting prices in the 50-100 yuan range in 2024, up 17.22% from 2023 [14][15]. - The demand for personalized and functional health products is rising, particularly among younger consumers and new parents [81][84]. Future Outlook - By 2025, nearly 42% of companies anticipate that tightening policies and consumer downgrade will hinder rapid growth in the industry [35]. - Brands are expected to shift their focus towards value-driven strategies, including price adjustments and new channel explorations, to sustain growth [37][41].

证券研究报告 | 金融工程 2025 年 05 月 24 日 刚需+出海+历史低位，多重因素凸显制药价值 ——华宝中证制药 ETF 投资价值分析 随着保健意识的提升及国内人口老龄化趋势的发展，药品作为人们生活中的刚 性需求，其市场需求量日益增长。从供给端来看，原研药专利集中到期，创新 药频获出海订单，中药受政策大力扶持，各细分领域药企均迎来发展机遇。时 逢相关标的位于历史的价格低位，药品制造业显示出一定的投资机会。华宝中 证制药 ETF（认购代码：562053.OF）通过紧密跟踪中证制药指数，一键式配 置制药行业优质上市企业，值得投资者关注。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 在新兴市场经济快速发展和各国医疗保障制度的逐渐完整之下，全球医药 市场规模仍旧维持着稳定增长态势。而据统计，我国的人均药品用量仍远 低于世界发达国家水平，国内药品用量的需求增长仍然具有较大的空间。 ❑ 在供给端，各细 ...

Core Viewpoint - Tongrentang reported a slight increase in revenue and net profit for Q1 2025, but concerns remain regarding the sustainability of this growth due to high inventory levels and declining sales of core products [2][3][4]. Financial Performance - In Q1 2025, Tongrentang achieved revenue of 5.276 billion yuan, a marginal increase of 0.16% compared to 5.267 billion yuan in Q1 2024 [3]. - The net profit attributable to shareholders was 582 million yuan, reflecting a year-on-year growth of 1.10% [3]. Inventory and Sales Concerns - The company faces significant inventory issues, with inventory turnover days increasing from 294.21 days in 2022 to 346.65 days in 2024 [6]. - Sales volumes for key product categories, such as cardiovascular and tonic products, decreased by 2.27% and 2.67% respectively [5][6]. Prepayment and Demand Weakness - Tongrentang's contract liabilities, particularly prepayments, halved year-on-year to 311 million yuan, indicating weak sales performance [8][9]. Cost Pressures - The company is experiencing substantial cost increases due to raw material price hikes, with natural cow bile prices rising nearly threefold from 430 yuan per gram in 2020 to 1700 yuan per gram in 2025 [10]. - The total inventory value increased from 9.316 billion yuan at the beginning of 2024 to 10.708 billion yuan by the end of the year, a growth of approximately 14.94% [10]. Profitability Challenges - The gross profit margin has declined by 3.34 percentage points in 2024, with retail and wholesale margins decreasing by 2.55 and 6.60 percentage points respectively [15]. - Despite price increases for products, the company’s ability to maintain profitability is under scrutiny as cost growth outpaces revenue growth [14][16].

Core Viewpoint - Tongrentang is leveraging a multi-faceted strategic layout to enhance its performance in the health industry by extending its industrial chain, accelerating the transformation of scientific research results, and advancing digital transformation [1] Financial Performance - In Q1 2025, the company reported revenue of 5.276 billion yuan, a year-on-year increase of 0.16%, and a net profit attributable to shareholders of 582 million yuan, up 1.10% year-on-year [2] - The net cash flow from operating activities improved significantly from -252 million yuan in the same period last year to 833 million yuan, attributed to optimized raw material procurement and a more reasonable inventory structure [2] - Total assets reached 32.312 billion yuan, a 3.57% increase from the end of the previous year, while net assets attributable to shareholders grew by 4.38% [2] Product Development and Innovation - The company launched a new specification for the product "Angong Niuhuang Wan," focusing on both tradition and innovation to provide high-quality traditional Chinese medicine products [3] - Research efforts led to the completion of 11 quality standard studies and 4 efficacy studies on various traditional Chinese medicine products [2] Digital Transformation and Supply Chain Management - The year 2025 marks the beginning of the "Pharmaceutical Industry Digital Transformation Implementation Plan," which aims to enhance production efficiency and quality control through digital means [4] - Tongrentang is accelerating its digital transformation, focusing on supply chain management, production efficiency, and consumer services, with a commitment to transparency throughout the production and sales processes [4] - The company has implemented a traceability management system for traditional Chinese medicine, ensuring comprehensive supervision and openness across the entire industry chain [4] Technological Advancements - The upgraded Traditional Chinese Medicine Knowledge Graph System 3.0, integrated with the DeepSeek model, enhances the intelligent integration and interaction of TCM knowledge, significantly improving service capabilities [5] Policy Alignment and Long-term Growth - Tongrentang's long-term strategy aligns with national policies, particularly the ongoing "Healthy China" initiative and the revitalization of traditional Chinese medicine [6] - The company aims to achieve a control rate of 70% for key processes in the TCM industry by 2030, focusing on smart manufacturing and big data analysis [6] - The company demonstrates resilience and vitality as a time-honored TCM enterprise, with expectations for enhanced core competitiveness amid the digital transformation wave [7]

Group 1: Market Trends and Growth - The health consumption market in China is expanding, with the total revenue of the health industry expected to reach 9 trillion yuan in 2024, up from 8 trillion yuan in 2021, indicating significant growth [2] - The demand for health services is shifting from a single focus on medical services to a diversified approach, leading to innovative business models and a variety of health-related products and services [2][4] - The popularity of "health tourism" and related activities reflects a change in consumer attitudes towards health and wellness, with a growing emphasis on quality of life and holistic health management [4][7] Group 2: Consumer Behavior and Preferences - Young consumers are increasingly prioritizing health-related spending, with "health maintenance" ranking among the top three expenditure categories for individuals aged 18-35 [8] - There is a notable rise in the consumption of health products among young people, with 78.2% of surveyed youth having paid for health products, indicating a shift towards nutrition and wellness [8][9] - The trend towards low-sugar and low-calorie health foods is gaining traction among younger demographics, with innovative products tailored to their preferences emerging in the market [8][9] Group 3: Technological Integration in Health Products - The integration of smart technology in health products is on the rise, with sales of health monitoring devices like smart wristbands increasing by 41.6% year-on-year in the first quarter [12] - Companies are leveraging artificial intelligence to enhance user experience in fitness apps, with platforms like "Keep" offering personalized training plans and a wide range of courses [12][13] - The demand for interactive and personalized health services is driving innovation in the health tech sector, leading to the development of smart fitness equipment and applications that cater to individual health needs [11][13]

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]

Core Viewpoint - A consumer complaint regarding the presence of foreign substances, including suspected stones, in Beijing Tongrentang's health tea has sparked significant public concern and media attention [1][2]. Group 1: Consumer Complaint - A consumer reported finding gray substances in the "Fuling Suanzao Ren Tea" purchased in November 2023, leading to a refund from the store [2][7]. - The consumer's video showing the foreign materials has gained traction on social media, raising questions about product quality [2][9]. - The product was sold for 59.8 yuan, and the consumer initially suspected something was wrong with the taste before discovering the foreign materials [2][8]. Group 2: Company Responses - Beijing Tongrentang's customer service stated that all products undergo strict quality inspections before sale, denying the presence of stones in their tea [7][8]. - The production company, Anhui Luoxuan Health Industry Co., Ltd., denied producing the disputed product and suggested that it may have expired, asserting that the quality does not match their standards [7][9]. - The company indicated that the consumer might have purchased a product not directly produced by Beijing Tongrentang, as they have ceased operations due to poor earnings [7][9]. Group 3: Industry Context - Recent reports have highlighted issues in the herbal tea market, including allegations of adulteration with soil and wood chips in products from Anhui Bozhou [9][11]. - The market for herbal tea in Bozhou has seen a rise in low-cost products, with some manufacturers admitting to using cheap substitutes to reduce costs [9][11]. - Bozhou's flower tea industry has over 640 production companies, generating an annual output value exceeding 100 billion yuan, indicating a significant market presence [11].